Table 2 Comparison of clinical features of patients receiving monotherapy ET and everolimus-based therapy
|  | Group A (CDKi in first line) | Group B (CDKi in second line) | Group C (CDKi in ≥ 3rd line) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Monotherapy ET n:34 | Everolimus-based therapy n:36 | p-value | Monotherapy ET n:16 | Everolimus-based therapy n:22 | p-value | Monotherapy ET n:17 | Everolimus-based therapy n:38 | p-value |
Median duration of CDKi, months (range) | 15 (9–46) | 19 (3–31) | 0.410 | 10 (3–34) | 13 (5–26) | 0.126 | 7 (3–14) | 11 (3–23) | 0.058 |
Age, median (range) | 57 (31–81) | 57 (37–86) | 0.920 | 53 (23–75) | 59 (37–74) | 0.293 | 58 (31–81) | 53 (36–80) | 0.392 |
ECOG PS, n (%) | |||||||||
 0 | 16 (47.1) | 15 (41.7) | 0.650 | 7 (43.8) | 12 (54.5) | 0.511 | 3 (17.6) | 17 (44.7) | 0.054 |
  ≥ 1 | 18 (52.9) | 21 (58.3) |  | 9 (56.3) | 10 (45.5) |  | 14 (82.4) | 21 (55.3) |  |
De-novo metastatic, n (%) | 21 (63.6) | 13 (36.1) | 0.022 | 6 (46.2) | 8 (36.4) | 0.568 | 7 (43.8) | 16 (44.4) | 0.963 |
Disease-free interval after (neo)adjuvant ET, n (%) | |||||||||
  ≤ 24 months | 6 (46.2) | 6 (26.1) | 0.044 | 1 (10.0) | 3 (21.4) | 0.558 | 5 (50.0) | 12 (54.5) | 0.321 |
  > 24 months | 5 (38.5) | 17 (73.9) |  | 6 (60.0) | 9 (64.3) |  | 4 (40.0) | 4 (18.2) |  |
 Unknown | 2 (15.4) | 0 (0) |  | 3 (30.0) | 2 (14.3) |  | 1 (10.0) | 6 (27.3) |  |
Post-CDKi metastatic site, n (%) | |||||||||
 Bone only | 16 (47.1) | 13 (36.1) | 0.175 | 6 (37.5) | 5 (22.7) | 0.288 | 0 (0) | 12 (31.6) | 0.061 |
 Bone + lymph node | 3 (8.8) | 1 (2.8) |  | 2 (12.5) | 1 (4.5) |  | 1 (5.9) | 1 (2.6) |  |
 Visceral only | 1 (2.9) | 6 (16.7) |  | 2 (12.5) | 1 (4.5) |  | 3 (17.6) | 3 (7.9) |  |
 Bone + visceral | 14 (41.2) | 16 (44.4) |  | 6 (37.5) | 15 (68.2) |  | 13 (76.5) | 22 (57.9) |  |